XT
ZBIO

XTX Topco’s Zenas BioPharma ZBIO Stock Holding History

XTX Topco’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
40,034
+20,723
+107% +$412K 0.01% 1777
2026
Q1 		$378K Buy
19,311
+7,128
+59% +$160K 0.01% 2280
2025
Q4 		$442K Buy
+12,183
New +$401K 0.01% 1718

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

XTX Topco's ZBIO Position: Q2 2026 in Review

XTX Topco increased its Zenas BioPharma (ZBIO) stake by 107% in Q2 2026, buying an estimated $412K and bringing the position to 40,034 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #1777.

XTX Topco first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • XTX Topco held 40,034 shares of Zenas BioPharma worth $1.02M as of Q2 2026.
  • XTX Topco bought 20,723 Zenas BioPharma shares in Q2 2026, an estimated $412K.
  • Zenas BioPharma made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1777 holding.
  • XTX Topco first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.